scholarly journals Coexistence of Chronic Lymphocytic Leukemia and Myeloproliferative Neoplasm

2014 ◽  
Vol 2014 ◽  
pp. 1-4
Author(s):  
Patrycja Zielinska ◽  
Miroslaw Markiewicz ◽  
Monika Dzierzak-Mietla ◽  
Anna Koclega ◽  
Grzegorz Helbig ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Present Report ◽  
Immune Surveillance ◽  
Myeloproliferative Neoplasm ◽  
Lymphocytic Leukemia ◽  
Western World ◽  
Simultaneous Occurrence ◽  
Secondary Neoplasms ◽  
High Incidence ◽  
Adult Leukemia

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the Western world. Host immune surveillance caused mainly by the disease itself is speculated to be responsible for high incidence of secondary neoplasms. However, the simultaneous occurrence of CLL and myeloproliferative disorder in the same patient is extremely rare. In the present report, a case of an 81-year-old man who was diagnosed with chronic lymphocytic leukemia and concomitant essential thrombocythemia is presented. We describe the morphologic, immunophenotypic, cytogenetic, and molecular findings in this patient. We also review the current literature.

scholarly journals Monoclonal B-cell lymphocytosis: a brief review for general clinicians

2011 ◽  
Vol 129 (3) ◽  
pp. 171-175 ◽  
Author(s):  
Daniel Mazza Matos ◽  
Roberto Passetto Falcão
Keyword(s):  
Clinical Practice ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Medical Condition ◽  
Routine Clinical Practice ◽  
Lymphocytic Leukemia ◽  
Western World ◽  
High Prevalence ◽  
Adult Leukemia ◽  
High Chance

Monoclonal B-cell lymphocytosis (MBL) is a recently described medical condition that displays biological similarities to the most common subtype of adult leukemia in the Western world, i.e. chronic lymphocytic leukemia (CLL). Diagnostic criteria have been published with the aim of differentiating between these two entities. The overall prevalence of MBL is at least 100 times higher than that of CLL, which indirectly suggests that MBL is not necessarily a pre-leukemic condition, although in some circumstances, CLL cases can really be preceded by MBL. In view of this high prevalence rate, general clinicians and even non-hematological specialists have a high chance of being faced with individuals with MBL in their routine clinical practice. MBL is classified as "clinical MBL", "population-screening MBL" and "atypical MBL" and the clinical management of affected individuals depends greatly on this differentiation. The present review provides a guide to diagnosing and following up MBL patients.

scholarly journals Identification of Clinically Relevant Subgroups of Chronic Lymphocytic Leukemia Through Discovery of Abnormal Molecular Pathways

2021 ◽  
Vol 12 ◽  
Author(s):  
Petr Taus ◽  
Sarka Pospisilova ◽  
Karla Plevova
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Western World ◽  
Molecular Pathways ◽  
Sequencing Data ◽  
Machine Learning Approach ◽  
Genetic Landscape ◽  
Genome Consortium ◽  
Adult Leukemia ◽  
Time To First Treatment

Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the Western world with a highly variable clinical course. Its striking genetic heterogeneity is not yet fully understood. Although the CLL genetic landscape has been well-described, patient stratification based on mutation profiles remains elusive mainly due to the heterogeneity of data. Here we attempted to decrease the heterogeneity of somatic mutation data by mapping mutated genes in the respective biological processes. From the sequencing data gathered by the International Cancer Genome Consortium for 506 CLL patients, we generated pathway mutation scores, applied ensemble clustering on them, and extracted abnormal molecular pathways with a machine learning approach. We identified four clusters differing in pathway mutational profiles and time to first treatment. Interestingly, common CLL drivers such as ATM or TP53 were associated with particular subtypes, while others like NOTCH1 or SF3B1 were not. This study provides an important step in understanding mutational patterns in CLL.

scholarly journals DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2) Is a Key Regulator and Molecular Marker in Chronic Lymphocytic Leukemia

2020 ◽  
Vol 21 (20) ◽  
pp. 7663
Author(s):  
Katarzyna Szoltysek ◽  
Carmela Ciardullo ◽  
Peixun Zhou ◽  
Anna Walaszczyk ◽  
Elaine Willmore ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Cell Biology ◽  
Cell Activation ◽  
Critical Role ◽  
Lymphocytic Leukemia ◽  
Western World ◽  
B Cell Activation ◽  
Expression Levels ◽  
Dap Kinase ◽  
Adult Leukemia

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the Western World and it is characterized by a marked degree of clinical heterogeneity. An impaired balance between pro- and anti-apoptotic stimuli determines chemorefractoriness and outcome. The low proliferation rate of CLL cells indicates that one of the primary mechanisms involved in disease development may be an apoptotic failure. Here, we study the clinical and functional significance of DRAK2, a novel stress response kinase that plays a critical role in apoptosis, T-cell biology, and B-cell activation in CLL. We have analyzed CLL patient samples and showed that low expression levels of DRAK2 were significantly associated with unfavorable outcome in our CLL cohort. DRAK2 expression levels showed a positive correlation with the expression of DAPK1, and TGFBR1. Consistent with clinical data, the downregulation of DRAK2 in MEC-1 CLL cells strongly increased cell viability and proliferation. Further, our transcriptome data from MEC-1 cells highlighted MAPK, NF-κB, and Akt and as critical signaling hubs upon DRAK2 knockdown. Taken together, our results indicate DRAK2 as a novel marker of CLL survival that plays key regulatory roles in CLL prognosis.

scholarly journals PD-1 inhibition in malignant melanoma and lack of clinical response in chronic lymphocytic leukemia in the same patients: a case series

2020 ◽  
Vol 27 (3) ◽  
Author(s):  
I. Landego ◽  
D. Hewitt ◽  
I. Hibbert ◽  
D. Dhaliwal ◽  
W. Pieterse ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Chronic Lymphocytic Leukemia ◽  
Meta Analysis ◽  
Case Series ◽  
Fold Increase ◽  
Lymphocytic Leukemia ◽  
Western World ◽  
Secondary Malignancy ◽  
Increased Risk ◽  
Adult Leukemia

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western world. Unfortunately these patients are often immunosuppressed and at increased risk of infection and secondary malignancy. Previous meta-analysis has found that patients with CLL are at a four-fold increase of melanoma compared to the general population. Recent advancements in our understanding of the programmed death (PD) receptor pathway have led to the advent of immunotherapies to target cancer cells. The use of PD-1 inhibitors is now considered first line treatment for BRAF wild-type metastatic melanoma. Interestingly, early pre-clinical data suggest that inhibition of this pathway may also be used in the treatment of CLL, however clinical trials now published were not successful. In this case series we highlight two cases where patients with CLL and concurrent malignant melanoma undergo treatment with PD-1 inhibitors, and were found to have reductions in their WBC counts but these were not sustained. These cases further illustrate that treatment of CLL with PD-1 inhibitors are ineffective treatment alone.

scholarly journals Therapeutic Targets in Chronic Lymphocytic Leukemia

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3259
Author(s):  
Luca Laurenti ◽  
Dimitar G. Efremov
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Therapeutic Targets ◽  
Common Type ◽  
Lymphocytic Leukemia ◽  
Western Countries ◽  
B Cell Malignancy ◽  
Adult Leukemia ◽  
Cell Malignancy

Chronic lymphocytic leukemia (CLL) is a common B cell malignancy and is the most common type of adult leukemia in western countries [...]

scholarly journals A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease

Blood ◽  
2011 ◽  
Vol 117 (20) ◽  
pp. 5463-5472 ◽  
Author(s):  
Davide Bagnara ◽  
Matthew S. Kaufman ◽  
Carlo Calissano ◽  
Sonia Marsilio ◽  
Piers E. M. Patten ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
T Lymphocytes ◽  
Adoptive Transfer ◽  
Severe Combined Immunodeficiency ◽  
Immune Surveillance ◽  
Lymphocytic Leukemia ◽  
Unknown Etiology ◽  
Lymphoid Tissues ◽  
Transfer Model

AbstractChronic lymphocytic leukemia (CLL) is an incurable adult disease of unknown etiology. Understanding the biology of CLL cells, particularly cell maturation and growth in vivo, has been impeded by lack of a reproducible adoptive transfer model. We report a simple, reproducible system in which primary CLL cells proliferate in nonobese diabetes/severe combined immunodeficiency/γcnull mice under the influence of activated CLL-derived T lymphocytes. By cotransferring autologous T lymphocytes, activated in vivo by alloantigens, the survival and growth of primary CFSE-labeled CLL cells in vivo is achieved and quantified. Using this approach, we have identified key roles for CD4+ T cells in CLL expansion, a direct link between CD38 expression by leukemic B cells and their activation, and support for CLL cells preferentially proliferating in secondary lymphoid tissues. The model should simplify analyzing kinetics of CLL cells in vivo, deciphering involvement of nonleukemic elements and nongenetic factors promoting CLL cell growth, identifying and characterizing potential leukemic stem cells, and permitting preclinical studies of novel therapeutics. Because autologous activated T lymphocytes are 2-edged swords, generating unwanted graph-versus-host and possibly autologous antitumor reactions, the model may also facilitate analyses of T-cell populations involved in immune surveillance relevant to hematopoietic transplantation and tumor cytoxicity.

scholarly journals Monosomy 12 and deletion of 13q34 in a case of chronic lymphocytic leukemia with concomitant lung cancer

2010 ◽  
Vol 67 (10) ◽  
pp. 864-866 ◽  
Author(s):  
Darko Antic ◽  
Marija Dencic-Fekete ◽  
Dragica Tomin ◽  
Irena Djunic
Keyword(s):  
Lung Cancer ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Lung Carcinoma ◽  
Prognostic Significance ◽  
Specific Treatment ◽  
Lymphocytic Leukemia ◽  
Simultaneous Occurrence ◽  
Hybridization Technique

Background. We described a patient with chronic lymphocytic leukemia (CLL) and lung cancer and unusual chromosomal aberrations. Case report. At the same time with the diagnosis of B-cell CLL, squamocellular lung carcinoma diagnosis was established. Using interphase fluoresecence in situ hybridization technique (FISH) we detected monosomy 12 and deletion of 13q34 occured in the same clone. One month after the beginning of examination the patient died unexpectedly during sleep immediately before we applied a specific treatment for CLL or lung carcinoma. Conclusion. Simultaneous occurrence of monosomy 12 and deletion of 13q34 in a patient with B-cell CLL has been described only once before, but as a part of a complex karyotype. The prognostic significance of these abnormalities remains uncertain.

scholarly journals Chronic Lymphocytic Leukemia B Cells Are Resistant to the Apoptotic Effects of Transforming Growth Factor-β

Blood ◽  
1997 ◽  
Vol 89 (3) ◽  
pp. 941-947 ◽  
Author(s):  
Raymond S. Douglas ◽  
Renold J. Capocasale ◽  
Roberta J. Lamb ◽  
Peter C. Nowell ◽  
Jonni S. Moore
Keyword(s):  
B Cells ◽  
Growth Factor ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Lymphocytic Leukemia ◽  
Western World ◽  
Spontaneous Apoptosis

Abstract Chronic lymphocytic leukemia (CLL) is the most common leukemia of the western world and is characterized by a slowly progressing accumulation of clonal CD5+ B cells. Our laboratory has investigated the role of transforming growth factor-β (TGF-β) and interleukin-4 (IL-4) in the pathogenesis of B-cell expansion in CLL. In vitro addition of TGF-β did not increase spontaneous apoptosis of B cells from most CLL patients, as determined using the TUNEL method, compared with a twofold increase observed in cultures of normal B cells. There was similar expression of TGF-β type II receptors on both CLL B cells and normal B cells. In contrast to apoptosis, CLL B-cell proliferation was variably inhibited with addition of TGF-β. In vitro addition of IL-4, previously reported to promote CLL B-cell survival, dramatically reduced spontaneous apoptosis of CLL B cells compared with normal B cells. CLL B-cell expression of IL-4 receptors was increased compared to normal B cells. Thus, our results show aberrant apoptotic responses of CLL B cells to TGF-β and IL-4, perhaps contributing to the relative expansion of the neoplastic clone.

Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study

2020 ◽  
Vol 40 (7) ◽  
pp. 4059-4066 ◽  
Author(s):  
BARTOSZ PULA ◽  
ELZBIETA ISKIERKA-JAZDZEWSKA ◽  
MONIKA DLUGOSZ-DANECKA ◽  
AGNIESZKA SZYMCZYK ◽  
MAREK HUS ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Observational Study ◽  
Lymphocytic Leukemia ◽  
Study Group ◽  
Term Efficacy ◽  
Adult Leukemia

scholarly journals Beetroot-Carrot Juice Intake either Alone or in Combination with Antileukemic Drug 'Chlorambucil' As A Potential Treatment for Chronic Lymphocytic Leukemia

2015 ◽  
Vol 3 (2) ◽  
pp. 331-336 ◽  
Author(s):  
Marie-Christine R. Shakib ◽  
Shreef G. N. Gabrial ◽  
Gamal N. Gabrial
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Present Report ◽  
Alternative Therapy ◽  
Substantial Reduction ◽  
Well Being ◽  
Daily Basis ◽  
Lymphocytic Leukemia ◽  
Carrot Juice ◽  
First Line ◽  
Progressive Accumulation

Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders (lymphoid neoplasms). It is characterized by a progressive accumulation of functionally incompetent lymphocytes. Patients with leukemia often seek unconventional treatments not prescribed by hematologist in order to improve their cancer treatment outcome or to manage symptoms. In the present report, a 76-year-old patient was diagnosed with B-cell chronic lymphocytic leukemia (B-CLL). Beetroot-carrot juice is used as a complementary and or/ alternative therapy used in conjunction with conventional leukemic treatment (chlorambucil) that has been a standard first-line chemotherapeutic agent for patients with CLL and known to have serious and undesirable side-effects. After one month and 15 days of administration of beetroot-carrot juice therapy, the patient had improved appetite, a sense of general well-being and increased vigor daily activities. Furthermore, beetroot-carrot juice was used as an adjuvant to chlorambucil resulted in a substantial reduction in leukocytes and lymphocytes count in peripheral blood and improvement in the relevant biochemical parameters.  Beetroot-carrot juice can be used as an effective treatment for CLL alone or in combination with chlorambucil when taken orally with regular diet on daily basis.

Sign in / Sign up

Export Citation Format

Share Document